Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CDK4/6 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT04968964
What this trial is testing

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 55
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableLooking for participantsNCT05795335
What this trial is testing

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
RenJi Hospital 172
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Testing effectiveness (Phase 2)Ended earlyNCT04738292
What this trial is testing

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Who this might be right for
ER-positive Breast CancerHER2-negative Breast CancerMetastatic Cancer
University of Wisconsin, Madison 11
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06650748
What this trial is testing

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerEarly-stage Breast Cancer
Peking University 100
Not applicableLooking for participantsNCT06171360
What this trial is testing

The Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT07432178
What this trial is testing

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Who this might be right for
Breast Cancer
Fudan University 2,288
Not applicableEnrolling By InvitationNCT07100054
What this trial is testing

Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

Who this might be right for
CDK4/6 InhibitorBreast CancerCYP3A4 Protein, Human+2 more
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 100
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Not applicableStudy completedNCT04943497
What this trial is testing

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,390
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509997
What this trial is testing

A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Lei Liu 30
Not applicableLooking for participantsNCT07215364
What this trial is testing

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

Who this might be right for
Early-stage Breast Cancer
Spanish Breast Cancer Research Group 74
Not applicableUnknownNCT04579484
What this trial is testing

Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study

Who this might be right for
Metastatic Breast Cancer
Sunnybrook Health Sciences Centre 20
Not applicableLooking for participantsNCT07524829
What this trial is testing

Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients

Who this might be right for
Breast CancerDrug-Related Side Effects and Adverse ReactionsChemotherapy Toxicity+2 more
Azienda Sanitaria Locale di Asti 124
Early research (Phase 1)WithdrawnNCT04585724
What this trial is testing

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Who this might be right for
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the Brain+1 more
Emory University
Not applicableLooking for participantsNCT07491380
What this trial is testing

Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)

Who this might be right for
Breast Cancer
Institut Curie 90
Not applicableActive Not RecruitingNCT07008508
What this trial is testing

Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study

Who this might be right for
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07290166
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.

Who this might be right for
Breast Cancer
Fudan University 42
Not applicableLooking for participantsNCT07273357
What this trial is testing

Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening

Who this might be right for
Geriatric AssessmentAdjuvant Drug TherapyBreast Cancer Early Stage Breast Cancer (Stage 1-3)
Region Jönköping County 200
Next Page